Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia.

Soncini M, Santoro F, Gutierrez A, Frigè G, Romanenghi M, Botrugno OA, Pallavicini I, Pelicci P, Di Croce L, Minucci S.

Biochim Biophys Acta. 2013 Jan;1832(1):114-20. doi: 10.1016/j.bbadis.2012.10.001. Epub 2012 Oct 6.

3.

Decitabine activates specific caspases downstream of p73 in myeloid leukemia.

Tamm I, Wagner M, Schmelz K.

Ann Hematol. 2005 Dec;84 Suppl 1:47-53.

PMID:
16193303
4.

Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine.

Lund P, Kotova I, Kedinger V, Khanwalkar H, Voltz E, Hahn WC, Gronemeyer H.

Mol Cancer Ther. 2011 Sep;10(9):1611-23. doi: 10.1158/1535-7163.MCT-11-0140. Epub 2011 Jun 22.

5.

5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.

Scott SA, Dong WF, Ichinohasama R, Hirsch C, Sheridan D, Sanche SE, Geyer CR, Decoteau JF.

Leuk Res. 2006 Jan;30(1):69-76. Epub 2005 Jul 25.

PMID:
16043219
6.

[Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell].

Meng YS, Ma XX, Meng XQ, Wei R, Liu W, Ai GW, Zhang YX.

Zhonghua Yi Xue Za Zhi. 2007 Dec 25;87(48):3406-10. Chinese.

PMID:
18476539
7.

Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.

Pettigrew KA, Armstrong RN, Colyer HA, Zhang SD, Rea IM, Jones RE, Baird DM, Mills KI.

Genes Chromosomes Cancer. 2012 Aug;51(8):768-80. doi: 10.1002/gcc.21962. Epub 2012 Apr 19.

PMID:
22517724
9.

Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.

Fabiani E, Leone G, Giachelia M, D'alo' F, Greco M, Criscuolo M, Guidi F, Rutella S, Hohaus S, Voso MT.

Leuk Lymphoma. 2010 Dec;51(12):2275-84. doi: 10.3109/10428194.2010.528093. Epub 2010 Nov 15.

PMID:
21077739
10.

Homoharringtonine and SAHA synergistically enhance apoptosis in human acute myeloid leukemia cells through upregulation of TRAIL and death receptors.

Cao H, Cheng Y, You L, Qian J, Qian W.

Mol Med Rep. 2013 Jun;7(6):1838-44. doi: 10.3892/mmr.2013.1440. Epub 2013 Apr 25.

PMID:
23620163
11.

AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia.

Barbetti V, Tusa I, Cipolleschi MG, Rovida E, Dello Sbarba P.

Cell Death Dis. 2013 Mar 14;4:e536. doi: 10.1038/cddis.2013.49.

12.

Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL.

Kaminskyy VO, Surova OV, Vaculova A, Zhivotovsky B.

Carcinogenesis. 2011 Oct;32(10):1450-8. doi: 10.1093/carcin/bgr135. Epub 2011 Jul 18.

13.

Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.

Kopp LM, Ray A, Denman CJ, Senyukov VS, Somanchi SS, Zhu S, Lee DA.

Mol Immunol. 2013 Jul;54(3-4):296-301. doi: 10.1016/j.molimm.2012.12.012. Epub 2013 Jan 16.

PMID:
23328088
14.

Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.

Yao Y, Zhou J, Wang L, Gao X, Ning Q, Jiang M, Wang J, Wang L, Yu L.

PLoS One. 2013 Aug 5;8(8):e70522. doi: 10.1371/journal.pone.0070522. Print 2013.

15.

Methylation silencing of the Apaf-1 gene in acute leukemia.

Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, Ishii H, Furukawa Y.

Mol Cancer Res. 2005 Jun;3(6):325-34.

16.

Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.

Berg T, Guo Y, Abdelkarim M, Fliegauf M, Lübbert M.

Leuk Res. 2007 Apr;31(4):497-506. Epub 2006 Oct 20.

PMID:
17056112
17.

Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.

Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M, Meuleman N, Kentos A, Martiat P, Willems L, Bron D.

Exp Hematol. 2007 Oct;35(10):1527-37. Epub 2007 Aug 13.

PMID:
17697742
18.

Induction of ID1 expression and apoptosis by the histone deacetylase inhibitor (trichostatin A) in human acute myeloid leukaemic cells.

Yu WP, Scott SA, Dong WF.

Cell Prolif. 2008 Feb;41(1):86-97. doi: 10.1111/j.1365-2184.2007.00499.x.

PMID:
18211287
19.
20.

Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.

Horak P, Pils D, Haller G, Pribill I, Roessler M, Tomek S, Horvat R, Zeillinger R, Zielinski C, Krainer M.

Mol Cancer Res. 2005 Jun;3(6):335-43.

Items per page

Supplemental Content

Write to the Help Desk